A randomized double-blind, double dummy, placebo-controlled, parallel-group, multicenter dose ranging study to evaluate the efficacy and safety of GW685698X inhalation powder once daily and fluticasone propionate inhalation powder twice daily compared with placebo for 8 weeks in adolescent and adult subjects with persistent asthma symptomatic on low-dose ICS therapy.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Fluticasone furoate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.
- 22 Sep 2010 Results presented at the European Respiratory Society congress, accoding to a GSK media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History